
Aligos Therapeutics (NASDAQ:ALGS) brought in sales totaling $367.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 13.86%, resulting in a loss of $37.71 million. In Q3, Aligos Therapeutics brought in $1.54 million in sales but lost $33.12 million in earnings.